Table 3 Summary of combination of targeted-therapy trials in IDH1/2-mutant newly diagnosed AML
Regimens | Phase | Patient Number | CR/CRi rate, % | Time to CR or response (median), months | OS (median), months | References |
|---|---|---|---|---|---|---|
HMA + venetoclax | Ib | 35 | 71 | 2.1 | 24.4 | [5] |
AZA + venetoclax | III | 46 | 75.4 | N/A | N/A | [7] |
AZA + venetoclax | Pooled data from two trials | 79 | 72 | 1.0 | 24.5 | [45] |
LDAC + venetoclax (HMA naïve) | Ib/II III | 18 | 72 | 1.4 | 19.4 | |
AZA + ivosidenib | Ib | 23 | 69.6 | 3.7 | N/A | [49] |
AZA + enasidenib | II | 68 | 68 | 5 | 22.0 | [50] |
Venetoclax + ivosidenib | Ib/II | 12 | 83 | NA | NA | [47] |
AZA + venetoclax + ivosidenib | Ib/II | 6 | 67 | NA | NA | [47] |